Revenues decreased by $0.4m, compared to the same period in 2010, primarily due to the timing of purchases by the company’s distribution partners.
Research and development (R&D) expenses decreased $0.4m during the three months, compared to the same period in 2010, primarily due to a decrease of $1.2m for contract manufacturing and pharmacovigilance studies for Duexis.
Horizon president and CEO Timothy Walbert said with the approval of the commercial manufacturing facility for Duexis, the company plans to begin shipping Duexis into the commercial pipeline in the US in the next few weeks.
"We also received notice of allowance on two key Duexis patents, providing potential exclusivity of Duexis out to 2026," Walbert said.
"Further, we advanced our near-term product portfolio via our submission of a new drug application to the FDA for our second product candidate, Lodotra, for the treatment of rheumatoid arthritis."
Horizon Pharma is a biopharmaceutical company that develops and medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.